Good morning :)
$
₹
Dr. Reddy’s Laboratories Ltd ADR

Dr. Reddy’s Laboratories Ltd ADR

RDY

NYSE
Asset Logo

Dr. Reddy’s Laboratories Ltd ADR

RDY

NYSE
$13.72—% (+13.72)
$
₹
$13.72—% (+13.72)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Unknown

Sector and industry information not available

Large Cap

With a market cap of $11.9B the stock is ranked 864

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

18.85
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.86
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.75
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

3.74
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

16.36%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.65%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 4 analysts reports

Buy
2 analysts
Hold
1 analyst
Sell
1 analyst

Price Upside

+2.33%

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Dr. Reddy’s Laboratories Ltd ADR 18.852.863.74
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare RDY with any stock or ETF
Compare RDY with any stock or ETF
Comparing from
RDY
LLY
JNJ
Loading...

Frequently asked questions

  1. Dr. Reddy’s Laboratories Ltd ADR (RDY) share price today is $13.72 as of October 27, 2026 at 12:56 AM IST. The stock touched a day high of $13.84 and a day low of $13.69.

  2. Dr. Reddy’s Laboratories Ltd ADR stock trades on NYSE under the ticker symbol RDY.

  3. Dr. Reddy’s Laboratories Ltd ADR's market capitalization is $11.87B as of October 27, 2026 at 12:56 AM IST.

  4. Dr. Reddy’s Laboratories Ltd ADR's price-to-earnings (P/E) ratio is 18.85 as of October 26, 2026.

  5. Dr. Reddy’s Laboratories Ltd ADR's price-to-book (P/B) ratio is 2.86 as of October 26, 2026.

  6. Yes, Dr. Reddy’s Laboratories Ltd ADR pays a dividend, with a current dividend yield of 0.65%.

  7. Yes, You can buy Dr. Reddy’s Laboratories Ltd ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Dr. Reddy’s Laboratories Ltd ADR shares in three steps: 1. Search Dr. Reddy’s Laboratories Ltd ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Dr. Reddy’s Laboratories Ltd ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Dr. Reddy’s Laboratories Ltd ADR (RDY) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.7285 shares at the current price of $13.72.

Loading...